Pulmonary Resection Combined with Isoniazid-and Rifampin-based Drug Therapy for Patients with Multidrug-resistant Tuberculosis

被引:1
作者
Park, Seung-Kyu [1 ]
Kim, Jin-Hee [1 ]
Kim, Jun-Ho [1 ]
机构
[1] Natl Masan TB Hosp, Dept Chest Surg, Masan, South Korea
关键词
Pulmonary tuberculosis; MDR-TB; Lung surgery;
D O I
10.4046/trd.2005.59.2.179
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background : To evaluate the clinical efficacy of pulmonary resection combined with first-line antituberculous drug therapy in patients with well-localized, cavities-containing pulmonary multidrug-resistant tuberculosis (MDR-TB). Method : From February 1998, seventeen patients with well-localized, cavities-containing pulmonary MDR-TB were enrolled and followed prospectively up to December 2004. After radical pulmonary resection, the patients were treated with antituberculous drugs comprising of isoniazid (H), rifampin (R), pyrazinamide (Z), ethambutol (E), and streptomycin (S) (3HERZS/3HERS/6HER). Results : All recovered isolates of M. tuberculosis were resistant to both isoniazid and rifampin, and to a mean of 4.8 antituberculous drugs (range, 2 to 7 drugs). Surgical procedures included lobectomy (13 patients), lobectomy plus segmentectomy (3 patients), and pneumonectomy (1 patient). The median time for postoperative sputum smear and culture conversion was 2 days (range, 1 to 23 days). Fifteen (94%) patients had durable cures (mean follow-up period, 39.0 months). One patient failed to convert her sputum and was successfully switched to second-line therapy; one patient developed active disease again almost 7 years later, likely due to re-infection with a new M. tuberculosis strain. Conclusion : Radical resection combined with administration of first-line antituberculous agents was effective in patients with well-localized, cavities-containing pulmonary MDR-TB.
引用
收藏
页码:179 / 185
页数:7
相关论文
共 26 条
[1]  
[Anonymous], 1996, REP SCH HLTH STAT SU, P1
[2]  
CANETTI G, 1961, ANN I PASTEUR PARIS, V101, P28
[3]   Worldwide incidence of multidrug-resistant tuberculosis [J].
Dye, C ;
Espinal, MA ;
Watt, CJ ;
Mbiaga, C ;
Williams, BG .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (08) :1197-1202
[4]   Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs [J].
Fish, DN ;
Choi, MK ;
Jung, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :1045-1049
[5]   SURGICAL INTERVENTION IN THE TREATMENT OF PULMONARY-DISEASE CAUSED BY DRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS [J].
ISEMAN, MD ;
MADSEN, L ;
GOBLE, M ;
POMERANTZ, M .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (03) :623-625
[6]  
ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108
[7]  
Jun HJ, 1997, KOR J THORAC CARDIOV, V30, P786
[8]   Mycobacterium tuberculosis growth at the cavity surface:: a microenvironment with failed immunity [J].
Kaplan, G ;
Post, FA ;
Moreira, AL ;
Wainwright, H ;
Kreiswirth, BN ;
Tanverdi, M ;
Mathema, B ;
Ramaswamy, SV ;
Walther, G ;
Steyn, LM ;
Barry, CE ;
Bekker, LG .
INFECTION AND IMMUNITY, 2003, 71 (12) :7099-7108
[9]  
Kim AJ, 1996, KOREAN J THORAC CARD, V29, P397
[10]  
Kwon ES, 1998, TUBERC RESP DIS, V45, P1143